CAS Number114798-26-4
Synonyms2-Butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol; nyl)-4-yl)methyl); Lorzaar; (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; LOS; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol; (2-butyl-4-chloro-1-{2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-imidazol-5-yl)methanol; Losartan; dup89; (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazol-5-yl)methanol; 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole; MFCD00865831
Molecular FormulaC22H23ClN6O
Molecular Weight422.91
Purity≥98 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point682.0±65.0 °C at 760 mmHg
Melting Point183-184ºC
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 114798-26-4 |
| Catalog No. | 2A-9011236 |
| Chinese Name | 氯沙坦 |
| Synonyms | 2-Butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol; nyl)-4-yl)methyl); Lorzaar; (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; LOS; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol; (2-butyl-4-chloro-1-{2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-imidazol-5-yl)methanol; Losartan; dup89; (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazol-5-yl)methanol; 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole; MFCD00865831 |
| Molecular Formula | C22H23ClN6O |
| Molecular Weight | 422.91 |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 682.0±65.0 °C at 760 mmHg |
| Melting Point | 183-184ºC |
| Appearance | powder |
| Storage Condition | 0-10°C; store in inert gas; avoid air, heat |
| Packaging | III |
| Application | Losartan is an angiotensin II receptor antagonist that competitively binds to the AT1 receptor with angiotensin II, with an IC50 of 20 nM. |
| HTC | 2942000000 |
| MDL Number | MFCD19686114 |
| SMILES | OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2 |
| InChI | 1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) |
| InChI Key | PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | 4.3 |
| MSDS | msds/11236_1_114798_26_4.pdf |
| Use of | Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. Properties Name losartan Synonym More Synonyms Losartan Biological Activity Description Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. Related Catalog Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor Research Areas >> Cardiovascular Disease IC50: 20 nM (angiotensin II) In Vitro Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3]. References [1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12. [2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014. [3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31. [4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21. [5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. Chemical & Physical Properties Exact Mass 422.162201 PSA 92.51000 Index of Refraction 1.681 InChIKey PSIFNNKUMBGKDQ-UHFFFAOYSA-N Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : CHEMICAL NAME : 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)- CAS REGISTRY NUMBER : 114798-26-4 LAST UPDATED : DATA ITEMS CITED : HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - woman DOSE/DURATION : TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 124,775,1996 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - man DOSE/DURATION : 17500 ug/kg/17W-I TOXIC EFFECTS : Sense Organs and Special Senses (Taste) - change in function REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 347,471,1996 Safety Information Hazard Codes Xi: Irritant; RIDADR 3278 WGK Germany 3 Packaging Group III Hazard Class 4.3 HS Code 2942000000 Synthetic Route 2-BUTYL-4-CHLOR... 124751-00-4 114798-26-4 2-BUTYL-4-CHLOR... 124751-00-4 Methoxytripheny... 114798-26-4 4'-[(2-Buty... 114772-55-3 114798-26-4 Precursor & DownStream Precursor 9 CAS#:124751-00-4 2-BUTYL-4-CHLOR... CAS#:114772-55-3 4'-[(2-Butyl-4-... CAS#:114798-36-6 Losartan Carbox... CAS#:124750-99-8 Losartan potassium DownStream 8 CAS#:1070175-00-6 3-(methanesulfo... CAS#:2387-23-7 1,3-Dicyclohexylurea CAS#:1070174-97-8 4-(3-thioxo-3H-... CAS#:124751-00-4 2-BUTYL-4-CHLOR... |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| levofloxacin Mesylate | 226578-51-4 | 2A-9011174 |
| Lincomycin hydrochloride | 7179-49-9 | 2A-9011191 |
| Linezolid | 165800-03-3 | 2A-9011192 |
| Lisinopril | 83915-83-7 | 2A-9011203 |
| Lopinavir | 192725-17-0 | 2A-9011228 |
| Losartan Potassium | 124750-99-8 | 2A-0200254 |
| Marbofloxacin | 115550-35-1 | 2A-9011292 |
| Mefloquine | 53230-10-7 | 2A-9011319 |
| Meloxicam | 71125-38-7 | 2A-9011329 |
| Melphalan | 148-82-3 | 2A-9011330 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS